Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 23, 2024Blood AdvancesOpen Access

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMichael WangRutgers, The State University of New JerseyTRTadeusz RobakCopernicus Memorial HospitalKMKami J. MaddocksThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e68ab2b6db643587612932https://doi.org/10.1182/bloodadvances.2023012424
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,746 citations
  2. 2Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL2023 · 3 citations
  3. 315‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial ( MCL 2): prolonged remissions without survival plateau2016 · 220 citations
  4. 4Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review2022 · 3 citations